Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Net Cash Flow data on file, last reported at -$17.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 68.01% year-over-year to -$17.5 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 105.12% increase from a year earlier, with the FY2025 full-year figure at -$35.2 million, up 6.25% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$17.5 million, up from -$39.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for NTLA reached as high as $385.7 million in Q4 2022 and fell as low as -$229.4 million in Q1 2023.
• Historically, Net Cash Flow has averaged $1.4 million across 5 years, with a median of -$6.9 million in 2022.
• Across the five-year window, Net Cash Flow tumbled 1629.85% in 2023 and surged 459.45% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $385.7 million in 2022, then tumbled by 84.61% to $59.4 million in 2023, then advanced by 15.7% to $68.7 million in 2024, then plunged by 157.91% to -$39.8 million in 2025, then jumped by 56.08% to -$17.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$17.5 million in Q1 2026, -$39.8 million in Q4 2025, and $37.2 million in Q3 2025.